Extract

The purpose of this observational study is to broaden the knowledge of the known safety and efficacy profile of Keppra® (Levetiracetam) oral solution in epileptic infants younger than 12 months when treated according to routine clinical practice. Their data will be collected until they reach the age of 13 months.

Inclusion criteria

• Epilepsy

Country

• France
• Germany
• Greece
• Italy
• Poland
• Spain
• United Kingdom

Links

• nct
• ictrp